Crinetics Pharmaceuticals, Inc.
NASDAQCRNX has completed a remarkable repositioning since the Vertex Pharmaceuticals acquisition announcement: the short book that once represented nearly 13% of the free float has been cut to a fraction of its former size, and the stock is now trading squarely on deal mechanics at $84.36 — effectively pinned to the $85 per share cash bid. The short-side unwind is the headline data point…
CRNX short interest plummets 37.6% in one week to 4.6% of float, driven by Vertex acquisition unwind.
CRNX has completed a remarkable repositioning since the Vertex Pharmaceuticals acquisition announcement: the short book that once represented nearly 13% of the free float has been cut to a fraction of its former size,…
CRNX arrives at its August 4 earnings report in an unusual position: short sellers have dramatically unwound their bets even as the stock sits near double its price from a month ago, leaving the market more focused on…
Snapshot as of 23 Aug 2026
Crinetics Pharmaceuticals heads into the week with its stock having nearly doubled on a massive catalyst — while Wall Street responds by downgrading in unison, creating one of the more striking divergences in recent…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CRNX — free to start on ORTEX.
Sign up for free →Open CRNX on ORTEX